Johnson & Johnson reports TREMFYA benefits in axial psoriatic arthritis
- At Week 24, BASDAI scores improved by 3.3 points with TREMFYA Q4W and 2.9 points with Q8W, versus 2.1 points with placebo.
- MRI-assessed sacroiliac inflammation scores fell by 7.1 points with Q4W and 5.2 points with Q8W, compared with 2.4 points with placebo.
- The STAR study enrolled 411 biologic-naïve adults and included a 24-week placebo-controlled period followed by 24 weeks of active treatment.
- No new safety signals were identified; the study safety profile was consistent with TREMFYA’s established profile in psoriatic disease.
Phase 4 study results
Johnson & Johnson reported results from the Phase 4 STAR study of TREMFYA (guselkumab) in biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial inflammation. The trial met its primary and major secondary endpoints, showing improvements in axial symptoms and MRI-assessed sacroiliac joint inflammation versus placebo at Week 24.
Mean BASDAI scores improved by 3.3 points with TREMFYA 100 mg every four weeks (Q4W) and 2.9 points every eight weeks (Q8W), compared with 2.1 points with placebo. ASDAS-CRP scores improved by 1.5 and 1.3 points, respectively, versus 0.8 points with placebo. The company noted that Q4W dosing is not approved in the U.S.
MRI and safety findings
Sacroiliac joint inflammation, measured by MRI using the SPARCC score, decreased by 7.1 points with Q4W and 5.2 points with Q8W, compared with 2.4 points with placebo. Improvements in reported symptoms included spinal pain, stiffness, fatigue, joint symptoms and tenderness. The study also reported skin clearance with both dosing schedules. No new safety signals were identified.
Study design
STAR enrolled 411 participants. It was a randomized, double-blind, placebo-controlled study with a 24-week placebo-controlled treatment period followed by 24 weeks of active treatment. Participants had active psoriatic arthritis, MRI evidence of axial inflammation and elevated C-reactive protein despite previous treatment with non-biologic DMARDs, apremilast and/or NSAIDs.
Source: J&J